Stock ALCJ CROSSJECT
Add to a list
To use this feature you must be a member
Log inSign up

Crossject Share Price

Equities

ALCJ

FR0011716265

Medical Equipment, Supplies & Distribution

Market Closed - Euronext Paris
Other stock markets
 16:35:21 26/04/2024 BST 		5-day change 1st Jan Change
2.02 EUR +0.50% Intraday chart for Crossject -1.94% -59.36%
04-03 CROSSJECT : Patience is a virtue… hopefully AL
04-02 Crossject Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2023 12.83M 13.71M 1.1B Sales 2024 * 3.7M 3.96M 317M Capitalization 76.81M 82.13M 6.58B
Net income 2023 -8M -8.55M -685M Net income 2024 * -15M -16.04M -1.28B EV / Sales 2023 14.7 x
Net Debt 2023 * 25.8M 27.59M 2.21B Net Debt 2024 * 27.8M 29.72M 2.38B EV / Sales 2024 * 28.3 x
P/E ratio 2023 *
-3.54 x
P/E ratio 2024 *
-5.05 x
Employees 110
Yield 2023 *
-
Yield 2024 *
-
Free-Float 61.18%
More Fundamentals * Assessed data

Chart Crossject

Dynamic Chart

Latest news about Crossject

CROSSJECT : Patience is a virtue… hopefully AL
Crossject Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023 CI
CROSSJECT : Invest Securities slightly reduces its target CF
CROSSJECT : Securing the financing needs AL
Crossject: share price falls after convertible bond issue CF
Crossject Société Anonyme announced that it expects to receive ?12 million in funding CI
CROSSJECT : No news is not always good news... AL
Crossject: strategy advances, but visibility worries CF
CROSSJECT : Marketing initiative in the US AL
Crossject: Syneos Health hired for Zepizure in the USA CF
French Pharmaceutical Crossject Taps Syneos Health for US Commercialization of Epilepsy Rescue Treatment MT
CROSSJECT : A new distribution agreement in Northern Europe AL
France's Crossject Inks New Commercialization Deal for Epileptic Seizure Therapy in Northern EU MT
Crossject: commercial agreement in Northern Europe CF
Crossject Signs ZENEO(R) Commercialization Agreement for Northern Europe CI
More news

Analyst Recommendations on Crossject

CROSSJECT : Patience is a virtue… hopefully AL
CROSSJECT : Invest Securities slightly reduces its target CF
CROSSJECT : Securing the financing needs AL
CROSSJECT : No news is not always good news... AL
CROSSJECT : Marketing initiative in the US AL
More recommendations

Press releases Crossject

Crossject reports audited financial results for 2023 GL
Crossject trading on Euronext to resume as usual on Wednesday April 3 GL
Crossject advances in its U.S. Strategy and reports Financial Results for 2023 GL
Crossject gender equality score reaches 96/100 in 2024 GL
Crossject gender equality score reaches 96/100 in 2024 AQ
More press releases

News in other languages on Crossject

Le marché devient un peu timbré
En Direct des Marchés : Hermès, Schneider, Atos, Carrefour, Casino, Sanofi, STMicro, Meta...
Crossject communique ses résultats financiers audités pour 2023
Bolsa de Madrid: Después de Semana Santa, algo va mal
CROSSJECT : La patience est une vertu... espérons-le
More news

Quotes and Performance

1 day+0.50%
1 week-1.94%
Current month-35.87%
1 month-34.63%
3 months-61.15%
6 months-47.60%
Current year-59.36%
More quotes

Highs and lows

1 week
1.99
Extreme 1.99
2.22
1 month
1.83
Extreme 1.828
3.15
Current year
1.83
Extreme 1.828
5.96
1 year
1.83
Extreme 1.828
5.96
3 years
1.41
Extreme 1.408
5.96
5 years
1.04
Extreme 1.04
5.96
10 years
1.02
Extreme 1.02
11.25
More quotes

Managers and Directors - Crossject

Managers TitleAgeSince
Patrick Alexandre CEO
 Chief Executive Officer 61 07/08/01
Olivier Giré PRN
 Corporate Officer/Principal - 31/12/15
Isabelle Liebschütz PRN
 Corporate Officer/Principal - 31/12/12
Members of the board TitleAgeSince
Daniel Teper BRD
 Director/Board Member 64 06/06/23
Eric Nemeth BRD
 Director/Board Member 65 -
Philippe Monnot CHM
 Chairman 65 -
More insiders

Quotes

Date Price Change Volume
26/04/24 2.02 +0.50% 57,012
25/04/24 2.01 -5.63% 23,445
24/04/24 2.13 0.00% 15,621
23/04/24 2.13 -0.93% 26,766
22/04/24 2.15 +4.37% 36,418

Real-time Euronext Paris, April 26, 2024 at 04:35 pm

More quotes

Company Profile

Crossject specializes in manufacturing and marketing needleless drug self-injection. The group provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.
Sector
Medical Equipment, Supplies & Distribution
More about the company

Income Statement Evolution

More financial data

Ratings for Crossject

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.02 EUR
Average target price
5 EUR
Spread / Average Target
+147.52%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Drug Delivery Systems

1st Jan change Capi.
CROSSJECT Stock Crossject
-59.36% 82M
SEDANA MEDICAL AB Stock Sedana Medical AB
-10.84% 187M
Drug Delivery Systems
  1. Stock Market
  2. Equities
  3. ALCJ Stock